Skip to content

Antidepressant Treatment of AIDS Related Depression.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000390
Enrollment
Unknown
Registered
2000-01-18
Start date
Unknown
Completion date
Unknown
Last updated
2015-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Adult, Acquired Immunodeficiency Syndrome, Depression, Female, Human, Imipramine, Male, Middle Age, Acquired Immunodeficiency Syndrome -- *complications, Depression -- *drug therapy, Depression -- etiology, Imipramine -- *therapeutic use

Brief summary

To test the effectiveness treating AIDS related depression with imipramine hydrochloride. Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status. This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.

Detailed description

To test the effectiveness treating AIDS related depression with imipramine hydrochloride. Depression syndromes are commonly associated with chronic, disabling, and fatal diseases. Due to the relentless course of HIV infection, there is a certain reluctance to treat the associated depression. In other illness, it has been proven that treating the depression often results in improvement of overall health status. This is a placebo controlled trial. Half of the patients are given imipramine hydrochloride every day for 6 weeks. Assessment is done by self reports and the Hamilton Depression Rating Scale. Prior to entry all patients are given a psychiatric evaluation. There is a cross over phase in which placebo non responders are entered into an open-label study and given imipramine hydrochloride.

Interventions

Sponsors

GEIGY Pharmaceuticals
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years

Inclusion criteria

* Patient must be ambulatory and relatively good health. Even if unable to work at least able to partially care care for self and not demented. * May have been alcoholic or drug abuser 6 months previous. * Unspecified * CD4 Unspecified.

Exclusion criteria

* Non ambulatory patients or those requiring extensive help in self care are excluded. * Non ambulatory patients or those requiring extensive help in self care are excluded. * Current alcohol or drug abuse. * Unspecified

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026